Repligen (RGEN) Stock
Biologic medicine manufacturing materials and systems provider. Here's the price, business snapshot, and what's worth knowing about Repligen in August 2026.
Repligen Corporation is a specialised life‑sciences company that supplies consumables, materials and systems used in the manufacturing of biologic medicines such as monoclonal antibodies. Its product mix includes chromatography resins (notably Protein A), filtration systems and process‑intensification technologies that often generate recurring revenue from repeat purchases. The business benefits from long development cycles and close relationships with large biopharma customers, offering potentially resilient margins, but growth is tied to demand for biologics and capital spending in biomanufacturing. At a market capitalisation of about $8.8bn, Repligen can be seen as a mid/large‑cap service provider to the booming biologics industry. Key considerations for investors include product concentration, supply‑chain execution, competition and the potential for acquisitions to add scale. This is general educational information, not personal advice — values can fall as well as rise and suitability depends on your circumstances.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Repligen's stock, with a target price indicating significant growth potential.
Financial Health
Repligen is producing solid revenue and cash flow, with strong profit margins supporting its growth.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Recurring revenue model
Consumables such as resins and filters often lead to repeat sales, supporting stable revenue streams; however, past performance is not a guarantee of future results.
Process innovation focus
Solutions that increase manufacturing efficiency can drive adoption and higher margins, though technology cycles and competition may affect uptake.
Biologics market exposure
Demand for monoclonal antibodies and biosimilars supports long‑term growth potential, but revenue can be sensitive to industry spending and regulation.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
